Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma (Q39165973)

9 September 2017

title

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma (English)

1 reference

9 September 2017

0 references

1 reference

Florian Ewald

1

1 reference

9 September 2017

Nicole Grabinski

2

1 reference

9 September 2017

Astrid Grottke

3

1 reference

9 September 2017

Sabine Windhorst

4

1 reference

9 September 2017

Dominik Nörz

5

1 reference

9 September 2017

Lisa Carstensen

6

1 reference

9 September 2017

Katharina Staufer

7

1 reference

9 September 2017

Bianca T Hofmann

8

1 reference

9 September 2017

Frank Diehl

9

1 reference

9 September 2017

Kerstin David

10

1 reference

9 September 2017

Udo Schumacher

11

1 reference

9 September 2017

Björn Nashan

12

1 reference

9 September 2017

Manfred Jücker

13

1 reference

9 September 2017

language of work or name

English

0 references

publication date

29 May 2013

1 reference

International Journal of Cancer

9 September 2017

published in

1 reference

9 September 2017

volume

133

1 reference

9 September 2017

issue

9

1 reference

9 September 2017

page(s)

2065-2076

1 reference

9 September 2017

1 reference

Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States

21 January 2018

1 reference

Surgical management of cholangiocarcinoma

21 January 2018

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

21 January 2018

1 reference

AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

21 January 2018

1 reference

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors

21 January 2018

1 reference

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

21 January 2018

1 reference

Akt signaling and cancer: surviving but not moving on.

21 January 2018

1 reference

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

21 January 2018

1 reference

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

21 January 2018

1 reference

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.

21 January 2018

1 reference

Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model.

21 January 2018

1 reference

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

21 January 2018

1 reference

Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

21 January 2018

1 reference

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

mTOR phosphorylated at S2448 binds to raptor and rictor

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

21 January 2018

1 reference

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

21 January 2018

1 reference

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

Drug combination studies and their synergy quantification using the Chou-Talalay method

21 January 2018

1 reference

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.

21 January 2018

1 reference

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

21 January 2018

1 reference

Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.

21 January 2018

1 reference

AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines

21 January 2018

1 reference

Preventing the calorie restriction-induced increase in insulin-stimulated Akt2 phosphorylation eliminates calorie restriction's effect on glucose uptake in skeletal muscle

21 January 2018

1 reference

The Akt kinases: isoform specificity in metabolism and cancer

21 January 2018

1 reference

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

Akt inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28214

1 reference

9 September 2017

1 reference